Coste Catherine
Coste Catherine's purchase track record
Coste Catherine has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/26/2023 | BMRA | $6K | -56.7% | -54.0% | +11.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Biomerica reports Q1 earnings with lower EPS and sales. Biomerica released its first‑quarter results, showing earnings per share of $0.37 and revenue of $1.265 million, both lower than the prior year’s $1.38 million sales figure. The decline in sales highlights a contraction in top‑line performance for the quarter. The company’s shares are currently near the lower end of its 52‑week range, which may provide context for market participants.
Transaction History
| BLFS | ▼ Sell | Other | 13,871 | — | 10/6/2026 | View on chart |
| BLFS | ▲ Buy | Grant | 8,170 | — | 2/24/2026 | View on chart |
| BLFS | ▲ Buy | Grant | 5,701 | — | 3/18/2025 | View on chart |
| BMRA | ▲ Buy | Grant | 85,000 | $26K | 12/13/2024 | View on chart |
| BMRA | ▲ Buy | Open Market | 2,190 | $6K | 1/26/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Analyst Pieces Highlight BioLife Solutions' Customer Retention, Momentum
Two analyst pieces this week focused on BioLife Solutions. Diamond Hill pointed to the company's high switching costs, suggesting customers face barriers to moving to competitors, which can support steady revenue. ChartMill separately noted the stock shows strong growth momentum along with a potential breakout setup. The stock is trading near the lower end of its 52-week range, while analysts maintain an average price target around $31, well above current levels.
Analyst Pieces Highlight BioLife Solutions' Customer Retention, Momentum. Two analyst pieces this week focused on BioLife Solutions. Diamond Hill pointed to the company's high switching costs, suggesting customers face barriers to moving to competitors, which can support steady revenue. ChartMill separately noted the stock shows strong growth momentum along with a potential breakout setup. The stock is trading near the lower end of its 52-week range, while analysts maintain an average price target around $31, well above current levels.